The startup develops medical drugs that protect deoxyribonucleic acid from damage caused by retroelements, which are ancient viruses linked to cancer and age-related diseases. By neutralizing these retroelements, the company enables hospitals to conduct rapid hypothesis testing and accelerate clinical translation of treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Retroelements, remnants of ancient viruses within our DNA, can cause DNA damage and are implicated in the development of cancer and age-related diseases. Current treatment strategies often fail to directly address the underlying DNA damage caused by these retroelements.
Solution
The startup is developing a novel class of medical drugs designed to protect DNA from damage induced by retroelements. By neutralizing these retroelements, the drugs aim to prevent or mitigate the DNA damage that contributes to cancer and age-related diseases. This approach offers a new avenue for therapeutic intervention by targeting the root cause of DNA instability. The company's focus is on enabling rapid hypothesis testing and accelerating the clinical translation of these treatments, potentially leading to more effective therapies.
Target Audience
The primary target audience includes hospitals and research institutions focused on cancer research and the development of treatments for age-related diseases.
Features
- Drugs designed to neutralize retroelements.
- Protection of DNA from retroelement-induced damage.
- Potential application in cancer and age-related disease treatment.